ACADIA third quarter revenues decrease to $584,000 ACADIA Pharmaceuticals Inc. , a biopharmaceutical firm utilizing innovative technology to gasoline drug discovery and scientific development of novel remedies for central nervous system disorders, reported its unaudited financial results for the 3rd quarter ended September 30 today, 2011 www.medicine-rx.com . ACADIA reported a net lack of $5.1 million, or $0.10 per common share, for the third quarter of 2011 compared to a net loss of $4.2 million, or $0.11 per common talk about, for the third quarter of 2010. For the nine months ended September 30, 2011, ACADIA reported a net lack of $17.5 million, or $0.34 per common share, in comparison to a net loss of $14.0 million, or $0.37 per common talk about, for the comparable period of 2010.
Participating in the brand new York City meeting had been senior principal investigators from leading academic institutions like the University of California, San Diego, Harvard Medical College and Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Middle, Johns Hopkins, Yale University, MD Anderson Cancer Center, Mt. Sinai Hospital, Henry Ford Medical center, University of Miami, University of Florida and Dana-Farber Cancer Institute. Supply Exosome Diagnostics; Accelerate Brain Cancer Cure.. Brain cancer may be the leading reason behind death among children and adults under age 20. This year, more than 200,000 people in the usa will be identified as having the primary or metastatic mind tumor.